Vivin Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 04-07-2024
- Paid Up Capital ₹ 1.95 Cr
as on 04-07-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.75 Cr
as on 04-07-2024
- Revenue -99.16%
(FY 2020)
- Profit 643.94%
(FY 2020)
- Ebitda 99.17%
(FY 2020)
- Net Worth 0.03%
(FY 2020)
- Total Assets 0.03%
(FY 2020)
About Vivin Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.95 Cr.
The company has closed loans amounting to ₹4.75 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Botta Anuradha, Sarada Botta, Sumanth Botta, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231TG2010PLC068004
- Company No.
068004
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vivin Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Botta Anuradha  | Director | 13-Dec-2010 | Current |
| Sarada Botta | Director | 19-Apr-2010 | Current |
| Sumanth Botta | Director | 19-Apr-2010 | Current |
| Parvathaiah Botta | Director | 19-Apr-2010 | Current |
Financial Performance of Vivin Life Sciences.
Vivin Life Sciences Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 99.16% decrease. The company also saw a substantial improvement in profitability, with a 643.94% increase in profit. The company's net worth moved up by a moderate rise of 0.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vivin Life Sciences?
In 2020, Vivin Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vivin Drugs & Pharmaceuticals Private LimitedActive 13 years 4 monthsBotta Anuradha, Sumanth Botta and 1 more are mutual person
Vivin Laboratories Private LimitedActive 20 years 8 monthsBotta Anuradha, Sumanth Botta and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 17 Mar 2011 | ₹4.75 Cr | Satisfied |
How Many Employees Work at Vivin Life Sciences?
Unlock and access historical data on people associated with Vivin Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vivin Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vivin Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
